These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28803715)

  • 1. A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine.
    Cao YF; Tao H; Hu YM; Shi CB; Wu X; Liang Q; Chi CP; Li L; Liang ZL; Meng JH; Zhu FC; Liu ZH; Wang XP
    Vaccine; 2017 Sep; 35(37):5073-5080. PubMed ID: 28803715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years.
    Yu XY; Chen ZP; Wang SY; Pan HR; Wang ZF; Zhang QF; Shen LZ; Zheng XP; Yan CF; Lu M; Chen B; Zheng Y; Zhang J; Lv HK; Huang SJ
    Vaccine; 2019 Jul; 37(32):4581-4586. PubMed ID: 31262585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial.
    Zhu FC; Zhang J; Zhang XF; Zhou C; Wang ZZ; Huang SJ; Wang H; Yang CL; Jiang HM; Cai JP; Wang YJ; Ai X; Hu YM; Tang Q; Yao X; Yan Q; Xian YL; Wu T; Li YM; Miao J; Ng MH; Shih JW; Xia NS
    Lancet; 2010 Sep; 376(9744):895-902. PubMed ID: 20728932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults.
    Wu T; Huang SJ; Zhu FC; Zhang XF; Ai X; Yan Q; Wang ZZ; Yang CL; Jiang HM; Liu XH; Guo M; Du HL; Ng MH; Zhang J; Xia NS
    Hum Vaccin Immunother; 2013 Nov; 9(11):2474-9. PubMed ID: 23887167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HEV study protocol : design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh.
    Zaman K; Dudman S; Stene-Johansen K; Qadri F; Yunus M; Sandbu S; Gurley ES; Overbo J; Julin CH; Dembinski JL; Nahar Q; Rahman A; Bhuiyan TR; Rahman M; Haque W; Khan J; Aziz A; Khanam M; Streatfield PK; Clemens JD
    BMJ Open; 2020 Jan; 10(1):e033702. PubMed ID: 31959609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial.
    Chen Z; Lin S; Duan J; Luo Y; Wang S; Gan Z; Yi H; Wu T; Huang S; Zhang Q; Lv H
    Clin Microbiol Infect; 2019 Sep; 25(9):1133-1139. PubMed ID: 30711651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a recombinant hepatitis E vaccine.
    Shrestha MP; Scott RM; Joshi DM; Mammen MP; Thapa GB; Thapa N; Myint KS; Fourneau M; Kuschner RA; Shrestha SK; David MP; Seriwatana J; Vaughn DW; Safary A; Endy TP; Innis BL
    N Engl J Med; 2007 Mar; 356(9):895-903. PubMed ID: 17329696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fusion of C3d molecule with neutralization epitope(s) of hepatitis E virus enhances antibody avidity maturation and neutralizing activity following DNA immunization.
    Yang S; Wang C; Fang X; Zhai L; Dong C; Ding L; Meng J; Wang L
    Virus Res; 2010 Aug; 151(2):162-9. PubMed ID: 20451569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity.
    Zhang J; Zhang XF; Zhou C; Wang ZZ; Huang SJ; Yao X; Liang ZL; Wu T; Li JX; Yan Q; Yang CL; Jiang HM; Huang HJ; Xian YL; Shih JW; Ng MH; Li YM; Wang JZ; Zhu FC; Xia NS
    Clin Microbiol Infect; 2014 Jun; 20(6):O397-405. PubMed ID: 24118636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination.
    Su YY; Huang SJ; Guo M; Zhao J; Yu H; He WG; Jiang HM; Wang YJ; Zhang XF; Cai JP; Yang CL; Wang ZZ; Zhu FC; Wu T; Zhang J; Xia NS
    Clin Microbiol Infect; 2017 May; 23(5):336.e1-336.e4. PubMed ID: 27836809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of a recombinant hepatitis E vaccine HEV 239.
    Li SW; Zhao Q; Wu T; Chen S; Zhang J; Xia NS
    Hum Vaccin Immunother; 2015; 11(4):908-14. PubMed ID: 25714510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
    Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
    Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity difference between two hepatitis E vaccines derived from genotype 1 and 4.
    Wen J; Behloul N; Dai X; Dong C; Liang J; Zhang M; Shi C; Meng J
    Antiviral Res; 2016 Apr; 128():36-42. PubMed ID: 26850829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of a hepatitis E vaccine.
    Zhang J; Zhang XF; Huang SJ; Wu T; Hu YM; Wang ZZ; Wang H; Jiang HM; Wang YJ; Yan Q; Guo M; Liu XH; Li JX; Yang CL; Tang Q; Jiang RJ; Pan HR; Li YM; Shih JW; Ng MH; Zhu FC; Xia NS
    N Engl J Med; 2015 Mar; 372(10):914-22. PubMed ID: 25738667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis E virus: Current epidemiology and vaccine.
    Wu X; Chen P; Lin H; Hao X; Liang Z
    Hum Vaccin Immunother; 2016 Oct; 12(10):2603-2610. PubMed ID: 27184971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis E vaccine development: a 14 year odyssey.
    Wu T; Li SW; Zhang J; Ng MH; Xia NS; Zhao Q
    Hum Vaccin Immunother; 2012 Jun; 8(6):823-7. PubMed ID: 22699438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of new hepatitis E vaccines.
    Cao Y; Bing Z; Guan S; Zhang Z; Wang X
    Hum Vaccin Immunother; 2018; 14(9):2254-2262. PubMed ID: 29708836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A.
    Wang K; Zhou L; Zhang X; Song C; Chen T; Li J; Zheng M; Wang Y; Zheng Q; Zheng Z; Yu H; Wu T; Gu Y; Zhang J; Zhao Q; Li S; Xia N
    Antiviral Res; 2019 Apr; 164():154-161. PubMed ID: 30802475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the long-term antibody response of a hepatitis E vaccine.
    Chen S; Zhou Z; Wei FX; Huang SJ; Tan Z; Fang Y; Zhu FC; Wu T; Zhang J; Xia NS
    Vaccine; 2015 Aug; 33(33):4124-9. PubMed ID: 26126668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
    Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
    Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.